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Abstract: Immunological assays detecting antibodies against enteroviruses typically use a single
enterovirus serotype as antigen. This limits the ability of such assays to detect antibodies against
different enterovirus types and to detect possible type-specific variation in antibody responses.
We set out to develop a multiplexed assay for simultaneous detection of antibodies against multiple
enterovirus and rhinovirus types encompassing all human infecting species. Seven recombinant VP1
proteins from enteroviruses EV-A to EV-D and rhinoviruses RV-A to RV-C species were produced.
Using Meso Scale Diagnostics U-PLEX platform we were able to study antibody reactions against
these proteins as well as non-structural enterovirus proteins in a single well with 140 human serum
samples. Adults had on average 33-fold stronger antibody responses to these antigens (p < 10−11)
compared to children, but children had less cross-reactivity between different enterovirus types.
The results suggest that this new high-throughput assay offers clear benefits in the evaluation of
humoral enterovirus immunity in children, giving more exact information than assays that are based
on a single enterovirus type as antigen.
Keywords: enterovirus; rhinovirus; multiplex immunoassay
1. Introduction
Enteroviruses (EV) constitute a large group of common non-enveloped RNA viruses that cause
a wide variety of diseases ranging from mild skin conditions and respiratory problems to more
severe inflammation in the heart [1], central nervous system [2], or the pancreas [3]. Infections
in young infants can be life-threatening and infections at any age can cause irreparable damage.
The hand, foot, and mouth disease epidemics are also frequently caused by enteroviruses and have
led to severe encephalitis especially in China and Southeast Asia [4]. While the infections caused
by enteroviruses are common and there are more than 200 known serotypes of enteroviruses, there
are not many serological tools with wide coverage for diagnosing and studying them. Currently,
reverse transcription polymerase chain reaction (RT-PCR) is widely used to diagnose these infections
by detecting viral RNA in clinical samples. RT-PCR is a valuable tool when the sample can be taken
at the acute phase of infection, but it cannot detect already resolved recent infections and it does
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not routinely allow identification of the serotype that caused the infection [5,6]. This can lead to
wrong/false negative findings as the virus is present in a clinical sample only for a few days [7]. Species-
or strain-specific identification of enteroviruses is mainly performed by sequencing, which is both
labor intensive and costly.
In acute infections, such as enteroviral myocarditis, that causes mortality especially in neonates,
a fast diagnosis is important to immediately start the appropriate treatment [8]. Viral myocarditis is
hard to distinguish from other causes of myocarditis, and reliable diagnosis is important to offer the
patients right treatment [9]. However, direct detection of the virus is often difficult due the delay from
acute infection to the onset of symptoms of myocarditis, and serological assays are frequently used to
screen enterovirus infections from these patients.
Enterovirus infections have also been linked to chronic diseases. For example, they have
been linked to the development of chronic dilated cardiomyopathy, [10,11] type 1 diabetes [12–15],
and chronic pancreatitis [3], which can also be a risk factor for pancreatic cancer [16]. Rhinovirus
(RV) infections have been linked to asthma exacerbations [17]. Studies on possible role of enterovirus
infections in chronic diseases require large prospective follow-up cohort follow-ups where infections
should be diagnosed long before the disease onset. In such studies, serological assays offer clear benefits
since the samples do not need to be taken during the acute phase of the infection. This is particularly
important aspect in enterovirus infections since the majority of acute infections are subclinical.
Enterovirus species that infect humans include enteroviruses A through D (EV-A, EV-B, EV-C,
EV-D) and rhinoviruses A through C (RV-A, RV-B, RV-C). Since enterovirus VP1 capsid proteins have
the most sequence variation between serotypes and species, they are theoretically the best option
as antigen in assays aiming at detection of antibody responses against different enterovirus types.
However, they also contain the enterovirus group-specific N-terminal antigenic epitope, which binds
antibodies that have been induced by a wide variety of different enteroviruses [18]. We set out to see if
a panel of VP1-proteins from representatives of all human infecting enterovirus species could be used
to make an assay that can identify antibody responses to enteroviruses on a species level. To this panel
of species-specific antigens, we added conserved non-structural enterovirus proteins that we have
shown in a previous study to act as markers for an acute enterovirus infection in adults [19].
Prototype viruses representing different species of human enterovirus and rhinovirus including
CVA4 (EV-A), CVB1 (EV-B), PV1 (EV-C), EV-D68 (EV-D), RV-A89, RV-B14, and RV-C3 (nomenclature
according to International Committee on Taxonomy of Viruses (ICTV)) were selected based on their
previous use as vaccines or due to their pathogenicity. For example, PV1 was chosen since vaccinating
for it is a part of the national vaccination program in many countries and EV-D68 was selected due to
the serious epidemics in Western countries in recent years [20]. RV-A89 and RV-B14 were picked since
they are used in prototype vaccines and have been shown to produce cross-neutralizing antibodies [21]
and RV-C3 was chosen because this serotype has been associated with asthma [22,23].
As testing for multiple antigens using traditional ELISA, especially with an extensive set of
samples, is very labor intensive, and multiplexing platforms based on spotting cannot be changed
once the antigens have been plated, we decided to use something more flexible, and adapted the
test to Meso Scale Diagnostics (MSD) U-PLEX linker-based platform (Figure 1) which is simple, fast,
and allowed us to change the antigens on the fly. The resulting multiplexed serological assay is suitable
for evaluating the serological history with low sample volumes and can be quickly adapted to suit
different needs by changing individual antigens.
2. Materials and Methods
2.1. Production and Purification of Enterovirus Antigens
The proteases 2A and 3C were produced as described in [24]. Briefly, 2A and 3C sequences were
ordered as artificial genes from Life Technologies and cloned to pBVboostFGII [25] expression vector.
The proteins were expressed in BL21-AI (Life Technologies, Espoo, Finland) Escherichia coli (E. coli)
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strain and purified using HisTrap FF crude immobilized metal affinity chromatography columns (GE
Healthcare Bio-Science AB, Umeå, Sweden) [24].
VP1 sequences from EV-A, EV-B, EV-C, and EV-D (CVA-4, CVB1, PV1, EV-D68) and RV-A, RV-B,
and RV-C (RV-A89, RV-B14, RV-C3) were obtained from online databases (Table A1).
The sequences were obtained as synthetic gene strings from GeneArt. Hexahistidine-tags were
added to the 5′ end of the VP1s and the resulting sequences were flanked with restriction sites
(BamHI and EcoRI), as well as generic sequences for PCR-amplification (not included into expression
cassette). The gene strings were amplified with PCR and purified from agarose gel-electrophoresis.
Both the purified VP1 sequences and pGEX-2T vectors were cut with FastDigest Restriction Enzymes
BamHI and EcoRI (Thermo Scientific, Loughborough, UK), the plasmid was phosphatase treated with
FastAP (Thermo Scientific, Loughborough, UK), and the cut fragments were purified using agarose gel
electrophoresis. Ligation reactions were transformed into chemically competent Top 10 E. coli cells
using heat shock method and plated onto LB-Amp plates. Colonies were picked, minipreps prepared
and DNA-sequenced with in house Sanger sequencing service. The amino acid sequences of all the
recombinant VP1 proteins have been listed for easy comparison in Table A2.Microorganisms 2019, 7, x FOR PEER REVIEW 3 of 17 
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substrate and an MSD plate reader. 
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Figure 1. Multiplex assay development. epresentative VP1 protein sequences from all human
infecting enterovirus and rhinovirus species were equipped with an N-terminal GST-tag and a
C-terminal 6xhis-tag for purification after bacterial expression. The purified recombinant VP1 proteins
along with 2A and 3C proteases from CVB3 and a BSA control were biotinylated and each antigen was
coupled to a unique U-PLEX linker. During coating each U-PLEX linker coupled antigen would target
a specific site at the bottom of the well. After coating, the assay is run like a regular indirect ELISA,
except for having a secondary antibody with electrochemiluminescence tag, and a suitable substrate
and an MSD plate reader.
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For protein production, the verified plasmids were transformed into BL21 Star (DE3) E. coli and
small seed cultures prepared overnight at +37 ◦C. Larger expression cultures were inoculated with the
seed cultures and grown to OD600 0.6–0.8 at 37 ◦C and the VP1 production induced using 100 µM IPTG.
The culturing temperature was then lowered to 28 ◦C and the cultures were harvested the following
day. The bacteria were pelleted by 20 min centrifugation at 4,000 rcf. The pellet was resuspended into
pH 8.0 PBS and the bacteria lysed using sonication. The lysate was clarified by 20 min centrifugation
at 25,000 rcf and the supernatant incubated overnight with glutathione resin at +4 ◦C on shaking.
The resin was washed with the binding buffer and the protein eluted with a Tris buffer (50 mM Tris-HCl
500 mM NaCl, pH 8) including 40 mM glutathione and 20 mM imidazole. VP1 containing fractions
were pooled and bound to Histrap resin for 1 h at RT, washed with Tris buffer with 30% glycerol and
eluted with Tris buffer containing 500 mM imidazole.
Samples from each purification step were run on SDS-PAGE Criterion TGX stain-free gels and
transferred to nitrocellulose for Western blotting to analyze the purification process and the purities
of the final products. Nanogam a pooled human serum concentrate and a HRP-conjugated rabbit
anti-human IgG secondary antibody (Dako cytomations P0214) were used for detection. Protein
concentrations were measured using UV-VIS spectroscopy and Pierce BCA protein assay kit (23225).
Proteins were dialyzed into PBS pH 7.4 and biotinylated for 3 h with 20×molar excess of EZ-link
biotin reagent (Thermo Scientific, Rockford, IL, U.S.A., catalogue number #35389) at RT. Unbound
biotin was removed by dialysis. Relative degree of biotinylation was analyzed densitometrically with
a procedure resembling Western blotting: 10 µg of purified, biotinylated antigen were loaded on
ready–made BioRad Criterion TGX stain-free gels. Monobiotinylated BSA (biotinylation quantified
with a B4F assay [26]) was loaded (10 µg, 20 µg, 40 µg, 80 µg) onto the gel as a standard. After transfer,
the BSA-blocked membranes were incubated with 10 nM neutral chimeric avidin [27] o/n at +4 ◦C.
After a washing step an in-house rabbit-anti-avidin polyclonal antibody was used to detect the neutral
chimeric avidin bound to the biotnylated antigens. Unbound antibodies were washed away and an
HRP-conjugated horse-anti-rabbit antibody was used as a detection antibody. ECL reagent was added
to the washed membrane and the resulting chemiluminescence was imaged and densitometrically
quantified using Biorad Chemidoc instrument with Image Lab software. Nanogam was used as a
positive control sample to detect VP1 antigens in Western blot.
2.2. Setting Up the Multiplex Assay
U-PLEX Development Pack was obtained from Meso Scale Discovery. Linker reactions were
modified to the U-PLEX 10 kit standard so that molar excess of linkers to antigens was adjusted based
on the amount of biotins/antigen. For example: If antigen had four biotins, we used the recommended
amount of protein and if the antigen had three biotins, 1.33 times the recommended amount of the
biotinylated protein was included.
Linking reactions were incubated for 1 h at RT after which they were quenched using the stopping
buffer provided in the kit and equal volumes of each linker reaction solution were pooled together to
make the coating solution.
Fifty microliters of the coating solution was added to each well and incubated for 1 h RT with
shaking. The wells were washed thrice with 150 µL PBST and blocked with 50 µL 1% BSA in PBS.
After another washing step, the analytes were loaded in the wells.
To test the coating of the antigens, we incubated 10 nM sulfo-tagged neutral chimeric avidin in the
wells for 1 h at RT on shaking, washed the wells, added 150 µL of 2× sulfo-tag substrate and ran the
measurement with the MSD instrument. After receiving similar signals from all the antigens with the
coating control, we tested our positive control Nanogam. Once we established that the pooled serum
concentrate gave signal for all antigens, we moved on to analyzing the individual serum samples.
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2.3. Human Serum Samples
Serum samples from patients with confirmed acute enterovirus infection (n = 20) were obtained from
Turku University Hospital [19]. Control samples (n = 22) were collected from healthy individuals [19].
Another serum sample collection was obtained from the Diabetes prediction and prevention (DIPP)
consortium [28], total of 88 serum samples, with partially known enterovirus histories [15]. Finally, we
obtained 20 serum samples from healthy adults from Tampere biobank, sampled from individuals during
routine checkups. Sample information has been summarized in Table 1.
Table 1. Summary of sample groups.
Sample Group n
Adult IgM pos 1 20
Adult IgM neg 1 22
Adult biobank 20
Children 2 88
1 IgM tested with enteroviruses (EV)-A and EV-B VP1 proteins [19]; 2 Seroneutralization assays performed for
various EV-A and EV-B viruses [15].
2.4. Human Samples Ethics Statement
Enterovirus IgM positive serum samples were originally tested in the virus diagnostic laboratory
in Turku University Hospital for the diagnosis of patients’ acute enterovirus infections. The samples
were anonymized and used in the development of antibody tests. Control serum samples included
laboratory personnel and the participants of the Autoimmune defense and living environment-study
(ADELE) [29]. Serum samples from children were obtained from under two-year-old participants,
who were participating in the Diabetes prediction and prevention-study (DIPP) [28]. All participants
or their legal guardians gave informed consent.
2.5. Workflow for Antigen Preparation and Assay Run
After the production of each antigen and confirming their functionality individually in traditional
ELISA following the same protocol used previously [19], we biotinylated the antigens, added unique
U-PLEX linkers to them, pooled them prior to coating and followed the protocol outlined in Figure 1.
After confirming with a limited sample set, including Nanogam, that we obtained reasonable signals
for each of the antigens, we ran a more comprehensive set of samples.
2.6. Analysis of Results
Data analysis was carried out using R v. 3.6.1 in RStudio 1.2.1335 with the following packages:
GGAlly, ggplot2, dplyr and reshape2. Wilcoxon rank-sum test was performed for comparing groups.
Cutoffs were calculated as in Equation (1)
Mean(x) + 3 × sd(x) (1)
where x is signal from dilution buffer BSA spots (four replicate wells).
Min-max normalization was calculated with the following formula (Equation (2)).
scaled(x) = (((b − a) × (x −min(x))) / (max(x) −min(x))) + a (2)
where x, is a signal from the distribution of signals for an antigen across all (adult or child) participants,
a = 0 = desired minimum value after scaling and b = desired maximum value after scaling.
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3. Results
3.1. VP1 Antigens Belonging to All Human Enterovirus and Rhinovirus Species Were Produced in E. coli
and Characterized
VP1 proteins from all human infecting enterovirus species (EV-A to EV-D) as well as rhinovirus
species (RV-A to RV-C) were expressed in E. coli and purified as described in materials and methods
section, and their purity, biotinylation status (Figure 2A), and antigenicity (Figure 2B) were analyzed
with Western blotting before they were used in the multiplex assay. For CVA4, CVB1 and EV-D68
VP1s we observed double bands, which we have seen previously for various VP1 proteins [30],
and presumably the double band is a result of partial C-terminal proteolysis, as evident from
Figure A1C, where anti-histag detected all VP1s. Also, Nanogam (which we have also used as positive
control in the multiplex assay) recognized all VP1 proteins (Figure 2B). Nanogam detected the RV VP1s
most strongly as expected from a pooled human serum concentrate, since rhinoviruses are extremely
common. The bands observed between 20 and 30 kDa are most likely a result of proteolysis occurring
between GST and the VP1 part of the fusion protein, as the size matches with VP1 and we observed
3A6 and Dako 5D8/1 monoclonal antibodies (both of which target the EV group specific epitope [18,30])
recognizing this band in CVB1 sample (Figure A1B,D). These analyses confirmed that the antigen
preparations did not contain large amounts of impurities and that they are properly biotinylated to
function as antigens in the U-PLEX assay.
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Figure 2. Antigen quality control. (A) The detection of biotinylation using neutral chimeric avidin and
anti-avidin antibody. (B) Antigen detection in Western blot using pooled human serum (Nanogam).
3.2. Antibody Responses to VP1 Antigens Are Stronger in Acutely Infected Adults Than in Healthy Controls
We compared the antibody responses between the different adult groups based on their previous
capture IgM assay results [19] (Figure 3A) as well as between adults and children (Figure 3B).
Non-characterized adult serum samples collected from healthy individuals from Tampere biobank
collection were included in the analysis as representatives of population background. The antibody
responses towards EV and RV antigens are on average higher in IgM positive adult participants than
in IgM negative controls (Figure 3A). Similarly, we observed the range of antibody responses in the
previously non-characterized biobank samples overlapping both the responses in enterovirus IgM
negative and IgM positive samples (Figure 3A). We conducted Wilcoxon rank-sum test to study the
differences of IgM negative and positive groups and the found significant difference (p = 0.032) for the
2A protease response after Bonferroni correction (Table 2). Adults have on average 33 times higher
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VP1 and protease responses (p < 3.9×10−11, with Wilcoxon rank-sum test) than children under two
years old (Figure 3B).
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Figure 3. Different sample groups show variable raw signal ranges in antibody responses for EV
and RV antigens in the multiplex assay. (A) Adult serum antibody responses grouped by IgM status.
(B) Antibody responses grouped by the age groups of samples. * p < 0.05 in Wilcoxon rank-sum test
after correcting for multiple testing (see Table 2).
3.3. Antibody Responses to VP1 Antigens Are More Specific in Children Than in Adults
To study the specificity of the antibody reaction in the multiplex assay, we plotted the antibody
responses to antigen pairs both in adults and children (Figure 4). To reduce the background noise, we
considered everything below a log10(2.5) threshold (based on measured BSA signals from dilution
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buffer) to have a signal level of zero and subtracted the same value from remaining positive signals.
Scatterplots in Figure 4A,B show that there is a great deal of cross-reactivity in the adult antibody
responses, but very little in children. This difference is well summarized in the correlation coefficients
for antigen pairs.
Table 2. Results of Wilcoxon rank-sum test between IgM positive and negative adults.
Antigen p p Adj.1
CVA4 0.113 N.S.
CVB1 0.167 N.S.
PV1 0.082 N.S.
EV-D68 0.048 0.477
RV-A89 0.252 N.S.
RV-B14 0.167 N.S.
RV-C3 0.116 N.S.
2A 0.003 0.032
3C 0.030 0.296
BSA 0.470 N.S.
1 Bonferroni correction. Statistically significant results bolded.
To investigate antibody responses at the level of individual participants, we plotted the
min–max-normalized and scaled (Equation (2)) responses as radarplots for adults and children
(Figure 5A,D respectively). To keep in mind the cross-reactivity of antibody responses, we also plotted
the spearman correlation coefficients (Figure 5B,C). Figure 5A shows that the 20 IgM positive adults
have on average higher 2A and/or 3C responses than the IgM negative ones, but it is hard to pick out
the possible infecting agent based solely on VP1 responses as the signal levels are often similar for
several ones simultaneously, regardless of IgM antibody status. This is also reflected in the correlation
coefficients (Figure 5B), most notably for enteroviruses A–D. Comparing Figure 5B,C, which depict the
correlation of antigen responses in adults and children, the antibody responses in children are less
correlated than in adults. This is also evident when comparing individual responses (Figure 5A,D): In
adults we typically see multiple high signals simultaneously, whereas in children there are only one or
two high VP1 responses. Based on these results it seems like the antibody responses in children are
more species specific than in adults, likely reflecting their more limited infection history.
Microorganisms 2020, 8, 963 9 of 16
A
0 0.5 1.5 0.0 0.5 1.0 1.5
Corr:
0.0238
Corr:
0.0149
Corr:
0.168
Corr:
-0.0705
Corr:
0.0723
Corr:
0.18
Corr:
-0.0423
Corr:
-0.0231
Corr:
-0.000645
Corr:
0.318
Corr:
0.227
Corr:
-0.124
Corr:
-0.0567
Corr:
-0.0643
Corr:
0.118
Corr:
0.118
Corr:
0.116
Corr:
0.118
Corr:
-0.0365
Corr:
-0.0832
Corr:
0.0912
Corr:
0.218
Corr:
-0.0658
Corr:
-0.0588
Corr:
-0.0841
Corr:
-0.05
Corr:
0.212
Corr:
-0.0921
Corr:
-0.0315
Corr:
-0.105
Corr:
0.341
Corr:
0.211
Corr:
0.0742
Corr:
-0.0531
Corr:
-0.0611
Corr:
0.0184
Corr:
-0.0534
Corr:
-0.012
Corr:
0.172
Corr:
-0.0638
Corr:
0.372
Corr:
-0.0208
Corr:
-0.0458
Corr:
-0.0115
Corr:
0.257
1 2
0
1
2
3
4
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
0 0.5 1 1.5 2 0 0.5 1 1.5 2 0 0.5 1 1.5 2 0 0.5 1 1.5 2 0 0.5 1 1.5 2 0 0.5 1 1.5 2 0 0.5 1 1.5 2 0 0.5 1 1.5 2
2A BSACVB1 PV1CVA4 EV-D68 RV-A89 RV-B14 RV-C3
2A
3C
BSA
CVB1
PV1
RV-B14
RV-C3
HRVA 2A 3C
0.0 0.5 1.0
CVB1 PV1
3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
0.0
0.2
0.4
0.6
0 1 2 3 0 1 2
0
1
2
Cor : 0.3
Cor : 0.407
Cor : 0.222
Cor : 0.587
Cor : 0.347
Cor : 0.465
Cor : 0.551
Cor : 0.488
Cor : 0.534
Cor : 0.475
Cor : 0.65
Cor : 0.644
Cor : 0.677
Cor : 0.488
Cor : 0.266
Cor : 0.361
Cor : 0.437
Cor : 0.745
Cor : 0.64
Cor : 0.741
Cor : 0.789
Cor : 0.346
Cor : 0.558
Cor : 0.547
Cor : 0.605
Cor : 0.321
Cor : 0.37
Cor : 0.409
Cor : 0.453
Cor : 0.63 Cor : 0.678
Cor : 0.726
Cor : 0.757
Cor : 0.779
Cor : 0.863
Cor : 0.679 Cor : 0.668
Cor : 0.514
Cor : 0.501
Cor : 0.585
Cor : 0.435
Cor : 0.428
Cor : 0.614
Cor : 0.311
Cor : 0.524
0
1
2
3
3
0
1
2
3
0
1
2
3
0
1
2
3
0
1
2
3
0
1
2
3
0
1
2
3
0
1
2
3
CVA4 EV-D68 RV-A89 RV-B14 RV-C3
C
VA4
2A
3C
BSA
CVB1
PV1
EV-D68
RV-B14
RV-C3
BSA
RV-A89
3C
C
VA4
EV-D68
RV-A89
B
Figure 4. Scatterplots and correlations of antibody responses between different enterovirus antigens.
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and (B) children and in the upper diagonal shows the corresponding Spearman correlation coefficients.
In panel A, the diagonal shows the distribution of antibody responses grouped by IgM status: blue
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Figure 5. Antigen specific min-max normalized antibody responses and correlations of antibody
responses between different enterovirus antigens. Antigen specific min-max normalized antibody
responses (see Equation (2)) in the multiplex assay illustrated as radar plots for individual (A) adults
and (D) children. Radii of the sectors represent normalized signal intensities. Age grouped Spearman
correlations for antibody responses are illustrated as matrices for adults (B) and children (D). Min-max
normalization was performed separately for adults and children, due to differences in signal levels in
the two groups. Comparing (A) to (D) and (B) to (C), the differences between antibody responses in
adults and children become apparent.
4. Discussion
Immunological assays for studying enterovirus and rhinovirus infections when compared to
PCR-based methods answer a different question. While RT-PCR can identify the presence of a virus, it
will not tell anything about the immune response to it. Also, enteroviruses are detectable only for a
short window of time in the patient’s blood with RT-PCR, whereas antibody responses can be much
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longer lived. On one hand RT-PCR requires larger sample volumes, which can be a problem, when
running analysis from unique analytes with limited volume. On the other hand, due to the variability
of antibody responses, setting a clear cutoff threshold for determining acute infections for viruses as
common as enteroviruses and rhinoviruses can prove difficult and would require testing multiple
samples with known infection histories confirmed by other means. We believe that with further testing
we could use the antibody responses for non-structural proteins to assess how acute an infection is [19]
and narrow down the culprit with the responses against VP1 proteins.
The U-PLEX multiplex assay based on VP1 antigens from human infecting enteroviruses and
rhinoviruses produced interesting results. We showed that the antibody reactions to VP1 antigens
were stronger and had more cross-reactivity in adults than in children. Because the antibody responses
are more specific in children, this assay could be applied for testing cohort serum libraries collected
primarily from children. Running this multiplex assay for samples that have already been characterized,
initially to show repeatability of results, could further validate the specificity of the antibody responses.
Such validation would also tell if this assay could be suitable for clinical use as well.
The proteases 2A and 3C, included in the panel, gave similar results to our previous study focusing
on enterovirus-IgM negative and IgM positive adults [19]. In that study we found the antibodies
against viral proteases as potent markers for an acute infection in adults. Here, we found that children
often had high 3C reactivity, but low VP1 responses, indicating that either, protease specific antibodies
would not serve as marker for acute infections in children or that the VP1 responses in children are
more serotype specific than we expected. If the antibody responses to VP1s in children are indeed
more serotype than species specific, then it could explain why we see high responses to the proteases
which’ sequences are more conserved between enteroviruses than the VP1s’ [19,24]. This is plausible as
rhinovirus infections are the most common virus associated with wheezing in children aged between
one and two years according to a recent study [31]. Studying this phenomenon in high detail would
require samples from children confirmed to be acutely infected.
The multiplex assay is very flexible and fast to run. The U-PLEX platform is typically used
as a sandwich assay [32] and mostly for the detection and quantification of biomarkers, such as
interleukins [33]. However, it is possible to use any biotinylated molecules for coating as we did in this
study. The run time for two 96 well plates for this assay including sample preparation, coating and
incubations was roughly 5 h for one person. Therefore, a multiplexed approach for studying large
serum collections would greatly increase efficiency of cohort studies. The platform we chose is flexible
for prototyping assays as we can easily try different combinations of antigens. This simple change
could make the panel more relevant to Asian countries, where hand, foot and mouth disease caused
primarily by EV-A71 and CVA16 is prevalent, while the rest of the panel stayed the same. The authors
are unaware of any other immunology based multiplex assay for enteroviruses that has as broad
coverage as the one we describe in the current study. This kind of multiplexed assay could solve many
of the problems large scale studies such as DIPP [28] are facing. Because the assay is sensitive and
requires small sample volumes, less hands-on work is required in the laboratory and a smaller number
of plates needs to be run as opposed to regular ELISA. This also has the added benefit of reducing the
effects of inter-plate variation.
Studying the cross-reactivity of enterovirus antibody responses using this multiplex assay is
simple. Information on cross-reactivity could be important for studying prototype vaccines’ responses,
or if aiming to produce more accurate assays by reducing cross-reactivity. In recent years the
interest in vaccinating against enteroviruses that cause chronic diseases have gained more momentum
and prototype vaccines are being developed [34,35]. One major source of cross-reactivity between
enterovirus antibodies is the VP1 N-terminal enterovirus group-specific immunodominant epitope;
however, it is not a neutralizing one [18]. A similar epitope has been found in rhinoviruses, which
is highly conserved between them [36]. The presence of this epitope has been hypothesized to be
one reason why vaccines for the common cold caused by the more than 150 rhinovirus serotypes has
not been developed so far. Niespodziana and colleagues [36] discussed the possibility that as the
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antibody response towards this non-neutralizing epitope gets stronger with every new rhinovirus
infection, diverting resources from making neutralizing antibodies similarly to the classical example
first reported in influenza viruses and aptly termed the original antigenic sin [37,38].
There are a few possible strategies to make the assay less cross-reactive. One would involve
removing the enterovirus and rhinovirus specific epitopes from VP1 antigens and another one could
involve pre-incubating serum samples with said epitopes to reduce binding to the plated antigens.
Using this panel of antigens for studying the IgM fraction of sera could also make the test more
specific and relevant for diagnosing acute infections, as IgM responses have been shown to be less
cross-reactive than IgG-response [39]. Studying only the IgM antibodies would however require a
serum fractionation step prior to applying the samples to the assay if it is to stay on this platform. If
we achieved better specificity, it could be then possible to distinguish between serotypes as well as
species by looking at immune profile “fingerprint” patterns in antigen reactivity, revealing the recent
infection history.
5. Conclusions
We have developed a novel multiplex immunoassay covering all the enterovirus species. Using
human samples from confirmed enterovirus-infected and healthy individuals, we have shown that
the antibody responses towards different enteroviruses and rhinoviruses are more species specific
in children than in adults. We have also shown that the developed multiplex assay is versatile and
after further validation it has potential to find use in both patient diagnostics as well as for studying
pathogen-disease connections associated with enteroviruses and rhinoviruses in large cohort studies.
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Appendix A
Table A1. Details on VP1 antigens.
Species Serotype Genbank MW (kDa) PI Lysines
EV-A CVA4 AY421762.1 61.5 7.0 30
EV-B CVB1 AB646478.11 58.9 8.65 33
EV-C PV1 V01150.1 60.9 7.3 37
EV-D EV-D68 EF107098.1 61.7 7.78 38
RV-A RV-A89 M16248.1 61.7 7.68 38
RV-B RV-B14 AY355195.1 59.9 6.52 40
RV-C RV-C3 EF186077.2 58.2 6.23 36
Closest sequence on Genbank, the exact sequence is same as in [14].
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Table A2. Complete amino acid sequences of the recombinant VP1 antigens. VP1 parts unique to each
antigen are typed in bold.
Antigen Sequence
CVA4 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSGDAIADAIQNTVTSTIQRVTTNTVGQDATAANTAPSSHSLNTG
LVPALQAAETGASSTATDGNLIETRCVVNSNGTRETHIEHFFSRSGLVGVME
VDDTGTSGKGFSNWDIDIMAFVQLRRKLEAFTYMRFDAEFTFVTNLENGLT
NNSVIQYMYVPPGAPKPDARESFQWQTATNPSVFQKMDSPPPQVSVPFMSP
ASAYQWFYDGYPTFGPHSETSNLSYGQCPNNMLGTFSARVVSKQITNQKFQ
IRIYLRLKRVRAWIPRPLRSQPYIYRNYPTYGTTIQYLAKDRRKITETDYNAEQR
THPGHHHHHHPG
CVB1 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSGPVEESVERAMVRVADTVSSKPTNSESIPALTAAETGHTSQVVP
SDTMQTRHVKNYHSRSESSIENFLCRSACVYYATYTNNSKKGYAEWVINTR
QVAQLRRKLELFTYLRFDLELTFVITSAQQPSTATSVDAPVQTHQIMYVPPGG
PVPTKVTDYAWQTSTNPSVFWTEGNAPPRMSIPFISIGNAYSCFYDGWTQFS
RNGVYGINTLNNMGTLYMRHVNEAGQGPIKSTVRIYFKPKHVKAWVPRPP
RLCQYEKQKNVNFNPTGVTTTRSNITTTGAFPGHHHHHHPG
PV1 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSGLGQMLESMIDNTVRETVGAATSRDALPNTEASGPAHSKEIPA
LTAVETGATNPLVPSDTVQTRHVVQHRSRSESSIESFFARGACVAIITVDNSA
STKNKDKLFTVWKITYKDTVQLRRKLEFFTYSRFDMEFTFVVTANFTETNNG
HALNQVYQIMYVPPGAPVPEKWDDYTWQTSSNPSIFYTYGTAPARISVPYVG
ISNAYSHFYDGFSKVPLKDQSAALGDSLYGAASLNDFGILAVRVVNDHNPT
KVTSKIRVYLKPKHIRVWCPRPPRAVAYYGPGVDYKDGTLTPLSTKDLTTYP
GHHHHHHPG
EV-D68 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSLDHLDAAEAAYQIESIIKTATDTVKSEISAELGVVPSLNAVETGA
SSNTEPEEAIQTRTVINQHGVSETLVENFLSRAALVSKRSFEYKNHTSSKART
DKNFFKWTINTKSFVQLRRKLELFTYLRFDAEITILTTVAVNGSSNSTYMGLP
DLTLQAMFVPTGALTPEKQDSFHWQSGSNASVFFKISDPPARMTIPFMCINS
AYSVFYDGFAGFEKSGLYGINPA
DTIGNLCVRIVNEHQPIGFTVTVRVYMKP
KHIKAWAPRPPRTLPYMSIANANYRGKDRAPNALNAIIGNRESVKTMPHNI
VTTPGHHHHHHPG
RV-A89 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSLDHLDAAEAAYQIESIIKTATDTVKSEISAELGVVPSLNAVETGA
SSNTEPEEAIQTRTVINQHGVSETLVENFLSRAALVSKRSFEYKNHTSSKART
DKNFFKWTINTKSFVQLRRKLELFTYLRFDAEITILTTVAVNGSSNSTYMGLP
DLTLQAMFVPTGALTPEKQDSFHWQSGSNASVFFKISDPPARMTIPFMCINS
AYSVFYDGFAGFEKSGLYGINPA
DTIGNLCVRIVNEHQPIGFTVTVRVYMKP
KHIKAWAPRPPRTLPYMSIANANYRGKDRAPNALNAIIGNRESVKTMPHNI
VTTPGHHHHHHPG
RV-B14 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSGLGDELEEVIVEKTKQTVASISSGPKHTQKVPILTANETGATMP
VLPSDSIETRTTYMHFNGSETDVECFLGRAACVHVTEIQNKDATGIDNHREA
KLFNDWKINLSSLVQLRKKLELFTYVRFDSEYTILATASQPDSANYSSNLVVQ
AMYVPPGAPNPKEWDDYTWQSASNPSVFFKVGDTSRFSVPYVGLASAYNCF
YDGYSHDDAETQYGITVLNHMGSMAFRIVNEHDEHKTLVKIRVYHRAKHV
EAWIPRAPRALPYTSIGRTNYPKNTEPVIKKRKGDIKSYPGHHHHHHPG
RV-C3 VP1
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNL
PYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIA
YSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVL
YMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPP
KSDLVPRGSNPVEEFVEHTLKEVLVVPDTQASGPVHTTKPQALGAVEIGATA
DVGPETLIETRYVMNDNTNAEAAVENFLGRSALWANLRLDQGFRKWEINFQ
EHAQVRKKFEMFTYVRFDLEITIVTNNKGLMQIMFVPPGITPPGGKDGREW
DTASNPSVFFQPNSGFPRFTIPFTGLGSAYYMFYDGYDGTDDANINYGISLTN
DMGTLCFRALDGTGASDIKVFGKPKHITAWIPRPPRATQYLHKFSTNYNKPK
TSGSTELEPKHFFKYRQDITSITNLPGHHHHHHPG
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Figure A1. Western blot analysis for antigens. Lanes 1-7 are VP1 proteins for CVA4, CVB1, PV1 EV-D68,
RV-A89, RV-B14, RV-C3, lane 8 is BSA, and lane 9 is 2A. Panel (A) shows the Ponceau-staining of the
nitrocellulose membrane after transfer, (B) 3A6 anti-CVB1 monoclonal antibody, (C) anti-his antibody
and (D) Dako 5D8/1.
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